Diabetes Strategies the Difference for Novo, Sanofi

The video discusses the competitive landscape of the pharmaceutical industry, focusing on Novo Nordisk and Sanofi. Novo Nordisk is heavily reliant on its diabetes treatments, facing market pressure due to increased competition and biosimilars. Sanofi, while missing out on some acquisitions, is focusing on its cancer drug pipeline and maintaining a diverse portfolio. The industry is split between companies narrowing their focus and those diversifying. Changes in the insurance market, particularly due to Obamacare, are also impacting drug pricing and company strategies.

What recent changes are happening in the C-Suite of Novo Nordisk?

What is Sanofi's approach to acquisitions and how does it relate to their strategy?

How are companies like Astra Zeneca and GlaxoSmithKline approaching their portfolios?